Korsana: Best-in-class ambitions in the Alzheimer’s brain shuttle race

Korsana is entering the Alzheimer’s brain-shuttle race with a recipe for differentiation: match the fast plaque clearance and lower ARIA signals Roche has seen with trontinemab, while engineering out the anemia liability that has shadowed TfR-based shuttles — and doing it in a patient-friendly formulation designed for subcutaneous dosing at home.

The two anti-amyloid antibodies marketed to treat Alzheimer’s disease have already achieved what the field spent decades chasing: they made amyloid removal clinically relevant. Just as important for drug developers, they elevated amyloid PET from a research tool to an approvable surrogate endpoint, transforming one of the longest, riskiest paths in drug development into one where early clinical data can de-risk efficacy — and lock in dose and regimen — well before Phase III...